GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shinva Medical Instrument Co 600587.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

12.76

-0.16%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥9.74bn

FY2016FY2025

Net income

CN¥526.3m

FY2016FY2025

Free cash flow

CN¥319.1m

FY2016FY2025

Shareholders' equity

CN¥7.63bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥9.74bnCN¥10.02bnCN¥10.01bnCN¥9.28bnCN¥9.48bnCN¥9.15bnCN¥8.77bnCN¥10.28bnCN¥9.98bnCN¥8.36bn
Gross profitCN¥2.45bnCN¥2.56bnCN¥2.62bnCN¥2.42bnCN¥2.28bnCN¥2.06bnCN¥1.84bnCN¥2.01bnCN¥1.96bnCN¥1.68bn
Research and developmentCN¥442.0mCN¥436.1mCN¥443.4mCN¥401.3mCN¥296.0mCN¥197.5mCN¥164.1mCN¥124.9mCN¥156.6mCN¥144.8m
Operating incomeCN¥703.9mCN¥798.5mCN¥757.0mCN¥585.8mCN¥720.2mCN¥364.8mCN¥1.12bnCN¥249.0mCN¥450.6mCN¥266.6m
Net incomeCN¥526.3mCN¥691.6mCN¥654.0mCN¥500.1mCN¥556.5mCN¥234.1mCN¥861.3mCN¥22.8mCN¥65.5mCN¥34.6m
Diluted earnings per share0.871.141.010.951.050.471.640.060.130.08

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥14.82bnCN¥15.53bnCN¥15.59bnCN¥12.95bnCN¥11.61bnCN¥11.55bnCN¥11.61bnCN¥12.38bnCN¥12.42bnCN¥11.37bn
Cash and short-term investments—CN¥2.95bnCN¥3.29bnCN¥1.79bnCN¥1.67bnCN¥1.39bnCN¥1.15bnCN¥1.25bnCN¥1.54bnCN¥1.25bn
Total liabilitiesCN¥6.86bnCN¥7.54bnCN¥7.87bnCN¥7.16bnCN¥6.35bnCN¥6.70bnCN¥6.92bnCN¥8.22bnCN¥8.30bnCN¥7.35bn
DebtCN¥90.6mCN¥1.01bnCN¥1.03bnCN¥1.19bnCN¥1.19bnCN¥2.26bnCN¥2.95bnCN¥4.11bnCN¥4.13bnCN¥3.29bn
Shareholders' equityCN¥7.63bnCN¥7.60bnCN¥7.32bnCN¥5.39bnCN¥4.91bnCN¥4.38bnCN¥4.18bnCN¥3.31bnCN¥3.30bnCN¥3.25bn
Shares outstanding604m605m651m524m531m501m524m395m512m413m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥700.6mCN¥450.7mCN¥1.03bnCN¥388.0mCN¥1.40bnCN¥1.10bnCN¥630.9mCN¥653.2mCN¥947.1mCN¥188.7m
Capital spending−CN¥381.5m−CN¥420.9m−CN¥535.8m−CN¥247.6m−CN¥274.4m−CN¥191.3m−CN¥215.8m−CN¥726.3m−CN¥538.8m−CN¥683.2m
Free cash flowCN¥319.1mCN¥29.8mCN¥494.3mCN¥140.5mCN¥1.13bnCN¥906.8mCN¥415.1m−CN¥73.1mCN¥408.3m−CN¥494.4m
Dividends paid−CN¥342.6m−CN¥329.0m−CN¥103.8m−CN¥61.8m−CN¥40.6m−CN¥40.6m−CN¥18.3m−CN¥219.7m−CN¥228.5m−CN¥184.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥2.91bnCN¥2.25bnCN¥2.76bnCN¥2.19bnCN¥2.48bnCN¥2.31bnCN¥2.60bnCN¥2.24bn
Gross profitCN¥730.9mCN¥555.5mCN¥696.3mCN¥559.0mCN¥644.1mCN¥548.9mCN¥606.1mCN¥579.8m
Operating incomeCN¥285.6mCN¥188.9mCN¥171.0mCN¥63.7mCN¥271.3mCN¥190.3mCN¥72.1mCN¥160.9m
Net incomeCN¥161.2mCN¥124.1mCN¥92.0mCN¥48.6mCN¥225.3mCN¥160.5mCN¥74.6mCN¥132.7m
Diluted earnings per share0.270.210.150.080.370.270.120.22
Cash from operations———−CN¥23.0mCN¥406.0m−CN¥163.0m—−CN¥173.0m
Capital spending−CN¥16.0m−CN¥18.0m−CN¥83.0m−CN¥53.0m−CN¥73.0m−CN¥171.0m−CN¥146.0m−CN¥104.0m
Free cash flow———−CN¥76.0mCN¥333.0m−CN¥334.0m—−CN¥277.0m
Total assetsCN¥14.94bnCN¥14.71bnCN¥14.82bnCN¥15.08bnCN¥15.35bnCN¥15.32bnCN¥15.53bnCN¥15.39bn
Cash and short-term investments———CN¥2.77bnCN¥3.03bnCN¥2.61bnCN¥2.95bnCN¥2.52bn
DebtCN¥131.5mCN¥123.7mCN¥90.6mCN¥1.14bnCN¥1.02bnCN¥990.1mCN¥981.1mCN¥1.01bn
Shareholders' equityCN¥7.87bnCN¥7.78bnCN¥7.63bnCN¥7.83bnCN¥7.86bnCN¥7.79bnCN¥7.60bnCN¥7.49bn

Financial ratios

Data as of 7 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin25.1%25.5%26.1%26.1%24.1%22.5%
Operating margin6.5%8.4%7.8%6.8%8.4%5.1%
Net margin5.4%6.9%6.5%5.4%5.9%2.6%
Return on equity6.9%9.1%8.9%9.3%11.3%5.3%
Return on assets3.6%4.5%4.2%3.9%4.8%2.0%
Free cash flow yield13.8%11.1%18.5%9.3%24.3%19.7%
Revenue growth-2.8%0.1%7.9%-2.1%3.6%4.4%
Earnings growth-23.9%5.8%30.8%-10.1%137.7%-72.8%
Current ratio1.36x1.29x1.26x1.07x1.03x0.96x
Debt to equity0.01x0.13x0.14x0.20x0.20x0.54x
Equity ratio51.5%48.9%46.9%41.6%42.3%37.9%
Interest coverage15.28x17.58x16.69x10.76x10.28x3.78x
R&D as a share of sales4.5%4.4%4.4%4.3%3.1%2.2%
Buybacks as a share of market value0.2%7.0%-24.2%1.3%-5.9%4.3%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue1.6%1.2%2.6%
Operating income6.3%14.0%6.3%
Net income1.7%17.6%6.5%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin25.3%25.7%24.9%22.9%
Operating margin7.6%7.3%6.8%6.2%
Net margin6.2%6.1%5.5%4.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings16.514.619.717.323.623.46.7174.3101.0230.8
Price to sales0.91.01.30.91.40.60.70.40.71.0

Dividends and splits

Per share, in the currency the company pays

Paid for 17 years. Last went ex-dividend on 24 Oct 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year0.500.500.1150.1150.0770.0770.0350.039
  • 13-for-10 split · 6 Jun 2024
  • 2-for-1 split · 21 Jul 2014
  • 13-for-10 split · 24 Jun 2008
  • 1-to-1 reverse split · 9 Jun 2006
  • 7-for-5 split · 30 Jun 2003

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.